Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
Condition: Bacterial Conjunctivitis
MeSH terms: Conjunctivitis, Bacterial; Conjunctivitis
Intervention: PRO-157; Vigamox; Zymar®; Lagricel Ofteno®
Intervention description: PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution; Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution; Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution; Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
Intervention MeSH terms: Moxifloxacin; Gatifloxacin; Pazufloxacin; Ophthalmic Solutions; Hyaluronic Acid
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 150.0
Sex: All
Minimum age: 1 Day
Maximum age: 99 Years
Healthy volunteers: No

Summary:

      A randomized, double blind, phase II multicenter trial with the objective of assess the
      safety and efficacy of the PRO-157 ophthalmic solution in three different dosing regimens,
      versus Moxifloxacin, versus Gatifloxacin in patients with bacterial conjunctivitis.

      Number of participants: 300 eyes, 60 per group.

      Criteria for evaluation:

      Measurements of effectiveness: Main efficacy criterion It will be determined as effective if
      there is a reduction in number or species of bacterial flora by comparing the basal culture
      against the final culture among the five different patient groups.

      Reduction or absence of infection with the clinical evaluation through signs and symptoms.

      Safety Measurements: it will be determined by visual acuity and adverse events Patients
      recruited will be treated for 7, for protocol purpose, the infected eye (s) will be taken
      into account at the time of baseline, however the study medication and procedures will be
      applied and performed in both eyes to protect the healthy eye.

      The study is divided into the following evaluation periods:

      Visit 1 baseline (day 1), visit 2 (day 3), final visit (day 8) and a telephone call (day 23)
      for the evaluation of adverse events.

      Subjects will be allocated to any of the following regimen dosages:

        -  PRO-157 1 drop 2 times daily

        -  PRO-157 1 drop 3 times daily

        -  PRO-157 1 drop 4 times daily

        -  Moxifloxacin 1 drop 3 times daily

        -  Gatifloxacin 1 drop 3 times daily. All regimen dosage will have a duration of 7 days. An
           artificial tear preservative free (Lagricel Ofteno®) will also be applied 15 minutes
           before instillation of study drug, during study period.

      Data Analysis: The data will be analyzed by Intention to Treat (ITT) and per Protocol (PP) in
      which each of the variables is described, the ITT population will be constituted by all
      subjects recruited who have received at least one dose of the study, the PP population will
      be the subset of ITT composed of all subjects without any major deviation from the protocol
      and the bivariate analysis will be performed in this group.

      Continuous quantitative variables are expressed and presented by measures of central tendency
      and dispersion (mean, standard deviation and ranges). Qualitative nominal and ordinal
      variables are presented by means of frequencies and proportions. The level of significance
      was an alpha of 0.05 or less.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Obtained from physician office visit.

          -  Diagnosis of bacterial conjunctivitis (signs and / or symptoms and / or culture).

          -  Informed Consent signed and dated (consent of the parents for minor patients).

        Exclusion Criteria:

          -  absence of written informed consent.

          -  Women of childbearing age, without contraceptive use (oral contraceptive pill,
             contraceptive intrauterine device, contraceptive implant, patch or condom).

          -  Pregnant or breastfeeding women.

          -  Subjects that could not be evaluated partially or totally according to the protocol.

          -  Subjects with topical, systemic or intravenous medication with any type of antibiotic
             on the day of the baseline visit.

          -  Subjects with topical, systemic or intravenous medication with any type of medication
             that interferes decisively with the results of the study.

          -  Subjects with a hypersensitivity history to any component or analogues of the
             formulation product.

          -  Positive drug addiction (smoking, alcoholism, marijuana).

          -  Subjects with a history of participation in any clinical study in the last 40 days
             prior to their evaluation.

          -  incapacity to give informed consent owing to mental disorder or legal condition.

          -  Any major anomaly detected during the clinical examination, tests that could interfere
             with the performance of the study or with the efficacy and safety evaluations.